 Conditions Evaluated Include Oncology, PTSD, Rheumatoid Arthritis, Chronic Pain, Insomnia, Back Pain and Inflammatory Bowel Diseases Conducted by Leading Contract Research Organization for Cannabis Research, Survey Covered More Than 650 Patients Using FDA-Validated Questionnaires TORONTO, ON and GLIL YAM, ISRAEL ACCESSWIRE June 17, 2021 IM Cannabis Corp. IMC or the Company NASDAQ:IMCC, CSE:IMCC, a multi-country operator MCO in the medical and adult-use recreational cannabis sectors with operations in Israel, Germany and Canada, today unveiled proprietary data from a clinical survey evaluating medicinal cannabis therapy. The patient survey, conducted by Medicanl Ltd. 